| 5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil |
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. |
zacks.com |
2025-05-15 13:11:13 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript |
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings and welcome to ClearPoint Neuro, Inc. First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-14 02:02:14 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates |
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.16 per share a year ago. |
zacks.com |
2025-05-13 22:35:39 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Reports First Quarter 2025 Results |
Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2025. First Quarter Highlights Reported record quarterly revenue of $8.5 million, an 11% year-over-year increase compared with the first quarter of 2024; Grew total consumable product revenue by $2.6 million year-over-year, or 104%, including biologics and drug delivery cannulas, SmartFrame® Family Navigation devices, and ClearPoint PRISM® Laser Therapy Applicators; Received FDA Clearance for the ClearPoint 3.0 Software which includes both operating room navigation capability and enhanced laser therapy features. |
accessnewswire.com |
2025-05-13 20:40:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-05-13 15:01:09 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing |
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has entered into a note financing arrangement with Oberland Capital Management LLC ("Oberland Capital") of up to $105 Million, with $30.0 million of gross proceeds funded at closing. Additional note financing will be provided to the Company by Oberland Capital under the following terms: An additional $25.0 million at the option of the Company any time prior to December 31, 2026; and An additional $50.0 million at the option of the Company and Oberland Capital any time prior to December 31, 2026. |
accessnewswire.com |
2025-05-12 20:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro: Fundamentals Continue To Strengthen |
ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. |
seekingalpha.com |
2025-04-29 04:00:17 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025 |
SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 first quarter on Tuesday, May 13th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 first quarter on Tuesday, May 13th, at 4:30 p.m. |
accessnewswire.com |
2025-04-25 12:00:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen |
ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth. |
seekingalpha.com |
2025-02-28 01:18:47 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript |
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings. |
seekingalpha.com |
2025-02-26 21:17:32 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates |
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. |
zacks.com |
2025-02-26 20:30:32 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results |
Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended December 31, 2024. 2024 Full Year and Fourth Quarter Highlights Reported fourth quarter 2024 revenue of $7.8 million, a 14% year-over-year increase compared with the fourth quarter of 2023; Reported revenue of $31.4 million for the full year 2024, an increase of 31% over 2023 and representing the tenth consecutive year of growth; Overall product revenue, including biologics and drug delivery, grew 76% to $18.6 million for the full year as a result of the SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System and partner progression in clinical trials; Activated six new global centers in the fourth quarter for a total of 25 new centers in 2024, approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt; Quarterly operational cash burn of $1.2 million, bringing total 2024 operational cash burn of $9.0 million, a reduction of 35% versus 2023; and Reported cash and cash equivalents totaling $20.1 million as of December 31, 2024. |
accessnewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025 |
SOLANA BEACH, CA / ACCESS Newswire / February 14, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 fourth quarter and full year on Wednesday, February 26th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 fourth quarter and full year results on Wednesday, February 26th, at 4:30 p.m. |
accessnewswire.com |
2025-02-14 10:00:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula |
SOLANA BEACH, CA / ACCESS Newswire / February 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of European Medical Device Regulation (EU MDR) approval for the SmartFlow Neuro Cannula. The SmartFlow Cannula was previously cleared under the Medical Device Directive 93/42/EEC (MDD) and has now successfully achieved the more rigorous EU MDR certification well ahead of the 2027 deadline for Class III devices. |
accessnewswire.com |
2025-02-12 18:15:00 |
Czytaj oryginał (ang.) |
| CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0 |
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States. |
zacks.com |
2025-01-28 09:21:27 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0 |
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its ClearPoint Navigation Software Version 3.0. "As we prepare for the wave of new patients that will be treated with cell and gene therapies in the years ahead, it is crucial that ClearPoint helps healthcare providers be ready by providing simplified workflows, offering solutions to increase surgical capacity and expanding access to our hardware and software," commented Joe Burnett, President and CEO at ClearPoint Neuro. |
accessnewswire.com |
2025-01-27 18:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro (CLPT) Surges 22.5%: Is This an Indication of Further Gains? |
ClearPoint Neuro (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-01-22 06:21:10 |
Czytaj oryginał (ang.) |
| 4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run |
Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains. |
zacks.com |
2024-12-23 13:56:10 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain |
Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. |
accesswire.com |
2024-11-13 20:15:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro: Near-Term Volatility Is No Concern |
ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively, probably due to its high valuation and weak sequential growth. Volatile performance should be expected in the near term due to the company's size and the immaturity of growth initiatives. ClearPoint's margins are improving, and cash burn is minimal, which should ease concerns about dilution. |
seekingalpha.com |
2024-11-10 11:35:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Q3 2024 Earnings Call Transcript |
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2024-11-08 00:31:31 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Tops Revenue Estimates |
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.20 per share a year ago. |
zacks.com |
2024-11-07 20:30:33 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Reports Third Quarter 2024 Results |
Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024. Third Quarter Highlights Reported quarterly revenue of $8.1 million, a 41% year-over-year increase; Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase; Overall product revenue, including biologics and drug delivery, more than doubled year-over-year, growing 127% to $5.5 million; Activated five new global centers in the third quarter for a total of 19 new centers so far this year; approximately three times our historic activation rate; Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications; Full early repayment of the principal amount and interest on a $10 million convertible note leaving the Company with no outstanding debt as of September 30, 2024; Quarterly operational cash burn reduced to $1.2 million, a 33% year-over-year decrease; and Reported cash and cash equivalents totaling $21.6 million as of September 30, 2024. |
accesswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024 |
President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast Today SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE. |
accesswire.com |
2024-10-31 18:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024 |
SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. |
globenewswire.com |
2024-10-17 20:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro (CLPT) Soars 6.9%: Is Further Upside Left in the Stock? |
ClearPoint Neuro (CLPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-10-15 13:21:08 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro Announces Early Repayment of $10 Million Note |
ClearPoint Neuro clears all debt from balance sheet after early repayment of principal & interest on $10 million convertible note held by PTC Therapeutics |
globenewswire.com |
2024-08-26 20:05:00 |
Czytaj oryginał (ang.) |
| ClearPoint: Growth Tailwinds Are Only Just Beginning To Emerge (Rating Downgrade) |
ClearPoint's business is gaining momentum, with recent growth investments starting to pay off. Growth in system placements is an early indication of the potential boost that the OR system and laser therapy will provide. ClearPoint's biologics business also continues to progress. This was highlighted recently by uniQure's solid clinical trial data. |
seekingalpha.com |
2024-08-14 13:33:04 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro: My Favorite Growth Stock |
ClearPoint Neuro is an industry leader in providing tools for minimally invasive brain surgeries, neurosurgical laser therapy, and drug delivery to the brain. The company has established a deep moat by working with partners early in clinical work, making its products part of FDA submissions. Continuous growth is expected through partner programs, consulting fees, and possible royalties and milestone payments. |
seekingalpha.com |
2024-08-08 23:39:04 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call Transcript |
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Kyle Bauser - B. Riley Emily Christy - Stifel Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Second Quarter 2024 Financial Results Conference Call. |
seekingalpha.com |
2024-08-08 11:25:09 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates |
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago. |
zacks.com |
2024-08-07 23:05:55 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-31 15:06:24 |
Czytaj oryginał (ang.) |
| The 3 Best Brain-Computer Interface Stocks to Buy Now |
Brain-computer interface (BCI) technology creates a direct link between the brain's electrical activity and a digital device. This connection can bring a vast range of benefits in assisting, augmenting and repairing human cognitive functions. |
investorplace.com |
2024-07-27 13:00:00 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024 |
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. |
globenewswire.com |
2024-07-17 20:05:00 |
Czytaj oryginał (ang.) |
| 7 Growth Stocks That Could 5X in 5 Years |
Growth stocks have been on a wild ride for the past few years. The pandemic sent many soaring to unbelievable heights. |
investorplace.com |
2024-07-17 11:00:00 |
Czytaj oryginał (ang.) |
| Strength Seen in ClearPoint Neuro (CLPT): Can Its 16.9% Jump Turn into More Strength? |
ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-07-10 08:56:05 |
Czytaj oryginał (ang.) |
| ClearPoint Neuro: Solid Progress Still Not Reflected In The Share Price |
ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of new services in coming years. The full market release of ClearPoint's operating room and laser solutions should help to revitalize the rest of the business. |
seekingalpha.com |
2024-06-21 09:11:18 |
Czytaj oryginał (ang.) |